EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Outcome of Ruthenium-106 Brachytherapy for Uveal Melanoma and Retinal Vascular Tumors: A Retrospective Study

Saeed Karimi, Sadra Ashrafi, Seyyed Morteza Hosseini Imeni, Zahra Siavashpour

Journal of Current Ophthalmology · 2025-04 · 37 (2) · 247-255

DOI: 10.4103/joco.joco_248_24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Current Ophthalmology, online erschienen am 19.12.2025. Verfasst von Saeed Karimi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

To evaluate the efficacy and safety of brachytherapy in patients with uveal melanoma and retinal vascular tumors.

Methods

Patients who received Ruthenium-106 (Ru-106) plaque brachytherapy at the Torfeh Medical Center between March 2016 and March 2022 were examined in this retrospective case-series. We collected clinical data on tumor features, treatment details, and patient outcomes. These data were analyzed using SPSS software. Tumor regression was the primary outcome that was monitored, with complications being evaluated as secondary outcomes.

Results

Of the 80 patients, 55 had melanoma, 21 had vasoproliferative tumor (VPT), and 4 had retinal capillary hemangioma (RCH). Tumor regression was observed in 74.5% of melanoma cases and 100% of VPT/RCH cases. Significant relationships were found between tumor characteristics, such as thickness and dose rate at the apex, and treatment outcomes. Complications included radiation retinopathy and cataract formation, with recurrence rates of 16.4% in melanoma and 7.7% in VPT/RCH.

Conclusions

Ru-106 plaque brachytherapy is effective in treating various intraocular tumors, particularly VPT/RCH. Tumor thickness significantly influences treatment outcomes, emphasizing the need for tailored approaches in brachytherapy planning. However, small sample sizes for specific tumor types limited the generalization of the outcomes. Future research should focus on refining techniques and mitigating complications to improve patient outcomes in ocular oncology.

Schlagwörter

Stichwörter der Autor:innen

BrachytherapyIntraocular tumorOutcome

Autor:innen und Institutionen

  • Ophthalmic Research Center, Research Institute for Ophthalmology and Vision Science, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Department of Ophthalmology, Torfeh Medical Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Department of Radiation Oncology, Shohada-e Tajrish Educational Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Zitieren

APA

Karimi, S., Ashrafi, S., Hosseini Imeni, S. M., & Siavashpour, Z. (2025). Outcome of Ruthenium-106 Brachytherapy for Uveal Melanoma and Retinal Vascular Tumors: A Retrospective Study. Journal of Current Ophthalmology, 37(2), 247-255. https://doi.org/10.4103/joco.joco_248_24

Vancouver

Karimi S, Ashrafi S, Hosseini Imeni SM, Siavashpour Z. Outcome of Ruthenium-106 Brachytherapy for Uveal Melanoma and Retinal Vascular Tumors: A Retrospective Study. Journal of Current Ophthalmology. 2025;37(2):247-255. doi:10.4103/joco.joco_248_24

BibTeX
@article{Karimi2025,
  author = {Karimi, Saeed and Ashrafi, Sadra and Hosseini Imeni, Seyyed Morteza and Siavashpour, Zahra},
  title = {Outcome of Ruthenium-106 Brachytherapy for Uveal Melanoma and Retinal Vascular Tumors: A Retrospective Study},
  journal = {Journal of Current Ophthalmology},
  year = {2025},
  volume = {37},
  number = {2},
  pages = {247--255},
  doi = {10.4103/joco.joco_248_24}
}
Kostenlos starten →